Healthcare Due Diligence (2026): The 60-Day Overpayment Clock + 8-Workstream Playbook

Last updated: August 2026

I'm Sean Yu, co-founder of Peony, a virtual data room company. Before Peony I spent my career on the deal side, and healthcare is the vertical where I most often watch a clean-looking model hide the risk that actually decides the deal. In a healthcare acquisition, the substance of diligence is not whether the earnings are real — it is whether the organization is lawfully allowed to operate, allowed to get paid, and free of inherited billing liability the buyer would assume at close. A physician group can look profitable and still carry a coding pattern that becomes a False Claims Act problem the moment a new owner keeps billing the same way. That is why a healthcare review runs eight regulatory-and-reimbursement workstreams a normal deal never centers, and why the healthcare data room leads with licensure, payer contracts, and quality evidence before it ever opens the financials.

The named trap in this post is the 60-day overpayment clock. Under Section 1128J(d) of the Social Security Act and 42 CFR 401.305, an identified Medicare or Medicaid overpayment must be reported and returned within 60 days, and if it is not, retaining it becomes an "obligation" under the False Claims Act — treble damages plus a per-claim penalty of $14,308 to $28,619. Buyers can inherit that exposure through successor liability. It is the credible, cited version of the "billing trap" that lesser guides assert without a source. I run Peony, a data room company used by 6,800+ customers across M&A and healthcare, and this guide maps the eight workstreams, the overpayment mechanics, the billing-and-coding review, what reviewers can actually see under HIPAA, and how change-of-ownership reshapes the closing timeline — every external number attributed, and the tooling framed honestly, including where a specialist firm or an enterprise platform is the better call than us.

Quick answer: Healthcare due diligence is the buyer's review of a provider before an acquisition, and it turns on regulatory and reimbursement risk, not just the financials. The eight workstreams are licensure/enrollment, billing and coding, payer contracts, credentialing, quality and compliance, fraud-and-abuse (Stark and Anti-Kickback), corporate structure (corporate practice of medicine), and workforce. The decisive risk is the 60-day overpayment clock — an identified Medicare/Medicaid overpayment retained past 60 days is a False Claims Act "obligation" (treble damages plus $14,308–$28,619 per claim), and a buyer can inherit it through successor liability. PHI usually stays out of the room — buyers work on de-identified and aggregate data, and when a billing or chart audit needs PHI, the vendor signs a BAA (Peony does, on request). Cost scales with the workstream count; deals run long — about 8.6 months blended time-to-close across 334 Peony transactions in Q2 2026 — because payer enrollment and credentialing sit on the critical path.

---

Why is healthcare due diligence different in 2026?

Healthcare due diligence is different because the deal environment in 2026 pairs a recovering, divestiture-driven transaction market with a regulatory-liability regime that a buyer can inherit — so the review has to price legal exposure, not just earnings quality.

The market context first, with the numbers attributed. Hospital and health-system M&A rebounded hard at the start of the year: per Kaufman Hall's M&A Quarterly Activity Report, Q1 2026, the quarter saw 22 announced transactions combining for $14.5 billion in transacted revenue (the highest Q1 figure in recent years), with the smaller party averaging $657 million in revenue, and 6 of the 22 deals involved a for-profit acquirer — a striking shift given that across all of 2025 only one announced transaction did. Across the broader healthcare sector, LevinPro HC reported 459 publicly announced transactions in Q2 2026, down from 553 in Q1 and roughly 23% below the 503 deals in Q2 2025 — a cooling from the Q1 spike, but still a busy market. The through-line in Kaufman Hall's own commentary is portfolio rationalization, not distress: 15 of the 22 announced transactions (68%) involved a divestiture — health systems pruning facilities and service lines to refocus their portfolios — while financially distressed sellers accounted for roughly 18% of announcements, down sharply from 43.5% in 2025. For a buyer, that mix carries its own diligence stakes: a divested facility arrives with its billing history intact but its compliance infrastructure — the parent system's billing team, compliance officers, and payer-relations staff — staying behind, so the review has to establish what the asset looks like outside the system that ran it.

Now the part that makes this vertical its own discipline. A healthcare buyer can inherit the seller's Medicare and Medicaid billing liability through successor liability. In an ordinary business acquisition, a clean asset deal usually lets a buyer leave the seller's liabilities behind. In healthcare, that assumption is unreliable: the government can pursue successor liability on billing obligations, and where a Medicare provider agreement transfers by change of ownership, its history transfers with it. So a coding pattern the seller never corrected, an overpayment the seller identified and sat on, or a physician arrangement that violates Stark can become the buyer's problem after close. That single fact reorders the review — the financials matter, but the regulatory and reimbursement workstreams are what determine whether there is a clean business to buy at the price on the table.

The rest of this guide is the practitioner version of what that means: the eight workstreams, the overpayment clock that most often moves price, the billing-and-coding review, the HIPAA boundary on what a reviewer can see, the enrollment mechanics that stretch the timeline, and how to run the room without turning the diligence file into a compliance liability of its own.

What is healthcare due diligence?

Healthcare due diligence is the structured pre-acquisition review of a healthcare provider — a clinic, physician group, home-health agency, behavioral-health platform, imaging center, or health system — in which the buyer verifies that the target is lawfully licensed and enrolled, that its billing is supportable, that its contracts and credentials will survive a change of ownership, and that it carries no inherited fraud-and-abuse or overpayment liability the buyer would assume.

The plain-English distinction from a generic M&A review is the order of the questions. A standard diligence process asks, in effect, "are the earnings real and defensible?" A healthcare process asks the prior question first — "is this organization allowed to operate and get paid, and is that right transferable and clean?" — because if the answer is no, the earnings are irrelevant. That is why buyers, payers, and regulators all work top-down through licensure, payer contracts, credentialing, and quality evidence before they trust the financials, and it is why the healthcare data room hub organizes the provider-side file into eight categories with the regulatory evidence leading. This post does not re-derive that document tree — the hub owns it. What this post owns is the risk analysis layered on top of it: the workstreams, the overpayment clock, the billing review, and the enrollment timeline.

One scope note up front. Healthcare covers a dozen distinct deal types, and the regulatory center of gravity shifts across them. A physio or chiropractic clinic sale turns on owner-dependence and a quiet, confidential process — covered in the clinic sale data room guide. A therapeutics deal — biotech or pharma — runs on a fundamentally different, IP-and-clinical-data-centered file covered in the biotech data room guide. This post is the provider-side, reimbursement-and-regulatory playbook: the review that applies when the target bills payers for care. Where a deal touches a medical device, the FDA quality regime enters, and I flag that specifically below.

What are the 8 workstreams of a healthcare due diligence review?

A healthcare due diligence review runs eight workstreams in parallel, and each has a distinct question it answers and a distinct red flag it hunts for. The table is the map; the sections after it go deep on the three that most often move price — the overpayment clock, the billing-and-coding review, and the enrollment timeline.

Two things to read off this table. First, the workstreams are not independent — the overpayment-and-successor-liability analysis lives across workstreams 1 and 2, and the fair-market-value question in workstream 8 is also a Stark and AKS question in workstream 6, so the reviewers have to talk to each other. Second, several of these are load-bearing in a way a generic deal never sees: a Stark foot-fault is a strict-liability problem, and an unreturned overpayment is a multiplied FCA liability, so a "small" finding in the regulatory streams can outweigh a large one in the financials. The room has to let each workstream's reviewers work independently while keeping the cross-references visible, which is a permissions problem the data room section below addresses directly.

Why does the 60-day overpayment clock decide deal price?

The 60-day overpayment clock decides deal price because it converts a billing error into a quantifiable, multiplied False Claims Act liability that a buyer can inherit — so it gets priced into the deal, escrowed, or specifically indemnified rather than left as a soft risk. This is the single most important regulatory mechanic in provider-side diligence, and it is worth stating precisely, because the credible version is very different from the vague "watch out for billing problems" that lesser guides offer.

The rule. Under Section 1128J(d) of the Social Security Act (42 U.S.C. 1320a-7k(d)), implemented at 42 CFR 401.305, a person who has received a Medicare or Medicaid overpayment must report and return it by the later of 60 days after the overpayment is identified or the date a corresponding cost report is due. Miss that deadline and the retained overpayment becomes an "obligation" under the False Claims Act — which is what turns a repayment question into a fraud-liability question.

The 2025 change to the trigger. What counts as "identified" was rewritten. A CMS final rule published in the Federal Register on December 9, 2024 and effective January 1, 2025 replaced the older "reasonable diligence" standard with the False Claims Act's "knowingly" standard — actual knowledge, reckless disregard, or deliberate ignorance of the overpayment (tracking 31 U.S.C. 3729(b)(1)(A)). The same rule formalized a six-month (180-day) suspension of the 60-day deadline to allow a good-faith investigation and quantification. For a deal, the practical read is nuanced: the "knowingly" trigger is arguably narrower than "should have known through reasonable diligence," but the investigation clock and the FCA linkage mean a target that has spotted an anomaly is on a running deadline, and a buyer needs to know where in that cycle the target sits.

The penalties. The False Claims Act imposes treble damages — three times the government's loss — plus a per-claim civil penalty. For 2026, the per-claim penalty runs $14,308 at the minimum and $28,619 at the maximum (per DOJ's inflation-adjustment figures; the amounts are unchanged from 2025 because OMB canceled the 2026 cost-of-living adjustment under memorandum M-26-11). Because the per-claim penalty attaches to each individual claim, a systematic coding error spread across thousands of claims compounds fast — which is precisely why a coding pattern, not a one-off, is the thing diligence hunts for.

Successor liability makes it the buyer's problem. A buyer can inherit this exposure. The government can pursue successor liability on billing obligations, and a Medicare provider agreement that transfers by change of ownership carries its history with it. So the seller's unreturned overpayment does not necessarily stay with the seller.

The self-disclosure release valve. When an overpayment is confirmed, the response is usually not silence — it is disclosure. HHS-OIG's Self-Disclosure Protocol generally applies a minimum 1.5x damages multiplier rather than the FCA's treble damages, sets a minimum settlement (higher for Anti-Kickback matters than for other conduct), and CMS will suspend the obligation to return the overpayment while an OIG settlement is negotiated. A confirmed, sized issue disclosed through the SDP is materially cheaper than the same issue litigated as an FCA case, which is why the diligence goal is to find and quantify the exposure before close so the parties can choose the disclosure route deliberately.

How buyers structure the response. Here is a hypothetical to make the mechanics concrete (illustrative figures, not a real deal). Suppose a chart audit on a physician-group target estimates roughly $600,000 in single-damages overpayment exposure from an unsupported E/M coding pattern across two years. A buyer does not walk — it structures. It might carve a specific indemnity out of the general reps for identified billing risk (uncapped or separately capped, surviving longer than the general survival period), fund an escrow or holdback sized to a reasonable multiple of the single-damages estimate to cover a self-disclosure settlement, and make closing conditional on the seller initiating an OIG self-disclosure with defined cooperation. The purchase price may or may not move; what always happens is that the identified exposure gets allocated in writing. The alternative — ignoring the pattern and inheriting it — exposes the buyer to treble damages and per-claim penalties on every one of those claims. This is why the billing-and-coding review below is where healthcare diligence earns its fee.

How do you review billing, coding, and reimbursement risk?

You review billing and coding risk by testing whether the medical record supports what was billed, and you do it through four lenses that move from statistical screen to quantified exposure. This is the workstream that produces the overpayment estimate that drives the structuring above, and it is the one that most often requires a specialist rather than a generalist QoE team.

1. E/M coding distribution analysis. Compare the target's evaluation-and-management code distribution against specialty and peer benchmarks. Every specialty has a characteristic bell curve of complexity codes; a distribution that skews toward the highest-complexity, highest-reimbursement codes without a case mix to justify it is the classic upcoding signal. This is a screen, not a conclusion — a legitimately high-acuity practice can carry a high-complexity distribution — but it tells the reviewer where to aim the chart audit.

2. The chart audit. Pull a defensible sample of claims and verify each one against the underlying medical record: does the documentation support the code that was billed. The chart audit is the only step that converts a statistical anomaly into a quantified overpayment estimate, because it establishes the error rate that can be extrapolated across the claim population. Sample design matters — a random statistically valid sample supports extrapolation; a targeted judgmental sample surfaces specific problems faster but is harder to extrapolate. This is the step that touches protected health information, and it is where the HIPAA boundary in the next section becomes load-bearing.

3. Payer-mix and denial-rate analysis. Map revenue by payer and track the denial rate over time. A rising denial rate signals documentation or coding problems that will get worse under a new owner's billing, and a heavy concentration in one government payer signals reimbursement fragility if that payer's rules or rates change. Payer mix also shapes the successor-liability picture: government-payer revenue is where the FCA and the overpayment clock apply.

4. The reimbursement-change overlay. Layer on the reimbursement changes that will move revenue post-close independent of any coding issue — fee-schedule cuts, prior-authorization tightening, site-of-service payment differentials, and program-specific rule changes. A target's trailing revenue can look stable while a known upcoming reimbursement change quietly erodes the forward number.

Who runs this, honestly. The chart audit is usually run by a specialist coding, revenue-cycle, or healthcare-compliance firm, not a generalist quality-of-earnings team — the review requires certified coding expertise and it handles PHI, so it sits with people who do it for a living. The QoE team consumes the audit's error rate as an input to the earnings quality analysis; it does not perform the audit. The data room's job is to give that specialist a walled, watermarked view of exactly the sample under review and to log the access — it is the exchange and evidence layer, not the audit tool. Where the financial workstream needs the buyer-side accounting depth, our financial due diligence and quality of earnings guides cover the add-back, peg, and normalization mechanics that sit alongside the coding review.

What can reviewers actually see under HIPAA during diligence?

Under HIPAA, reviewers see de-identified and aggregate data by default, and identifiable patient records stay out of the diligence room — that is both the compliant posture and the market norm, and it is house canon across our healthcare coverage. Getting this boundary right is what keeps the diligence file from becoming a HIPAA liability of its own.

The default: de-identified and aggregate. Buyers underwrite a provider on payer mix, encounter and procedure volumes, quality and outcome metrics, and coding and billing summaries — none of which requires a named patient. Individual medical records transfer after close, through the separate HIPAA-governed process that moves a patient population to a new owner, not through the diligence room. Keeping charts out of the diligence file is the norm and the safe norm: it means the room never becomes a HIPAA liability if a link is forwarded or a viewer turns out to be a competitor. This is the same line our clinic sale, behavioral health, and HIPAA-compliant data rooms guides draw — de-identify for diligence, transfer records post-close.

The exception: when PHI must enter the room. Some healthcare diligence genuinely requires chart-level data — the billing and coding audit above, a clinical-data or real-world-evidence review, a revenue-cycle dispute that touches individual claims. In those, PHI is the substance of the review, and two things become load-bearing. First, the data room vendor must sign a Business Associate Agreement (BAA), because it is then creating, receiving, maintaining, or transmitting PHI on your behalf, which makes it a business associate under HIPAA (45 CFR 164.502(e)). Second, de-identify whatever you can before upload, under HIPAA Safe Harbor (45 CFR 164.514(b)(2)), which requires stripping 18 categories of identifiers — the same de-identify-before-upload discipline our clinical trial data sharing guide walks through for research data. The data room is the secure distribution layer, not the de-identification tool.

There is no HIPAA certification — so test for the BAA. This is the reframe the market gets wrong: HHS certifies no software as "HIPAA-compliant." The Department of Health and Human Services does not license, endorse, or seal any product against HIPAA. "HIPAA-compliant" means the vendor will sign a BAA and implements the HIPAA Security Rule safeguards — administrative (45 CFR 164.308), physical (45 CFR 164.310), and technical (45 CFR 164.312: access controls, audit controls, integrity, and transmission security such as encryption). Any vendor "HIPAA certification" you see is a third-party assessment or an internal program, not a government approval, so the durable test is the BAA and the safeguards, not the badge. Peony signs a Business Associate Agreement (BAA) on request, is SOC 2 Type II, encrypts with AES-256 at rest and TLS 1.3 in transit, and its AI Q&A and extraction never train on or retain your documents. For the vendor-by-vendor view of who actually publishes or commits to a BAA and on which tier, the HIPAA-compliant data rooms matrix is the reference. And because a stray identifier can re-introduce PHI even into a nominally de-identified room, many teams sign a BAA anyway as cheap insurance — so a single overlooked exhibit does not become a reportable breach.

How do change-of-ownership and payer enrollment reshape the closing timeline?

Change of ownership and payer re-enrollment reshape the timeline because the target's right to bill under its existing numbers does not transfer the instant the deal signs — the enrollment and credentialing mechanics sit on the critical path, and a buyer that fails to map them during diligence discovers a revenue gap after close.

Medicare change of ownership (CHOW). A change of ownership is reported to CMS on Form CMS-855A, and the defining feature of a Medicare CHOW is that the provider agreement generally transfers to the new owner — which is a double-edged fact. It preserves billing continuity (the buyer keeps billing without a fresh enrollment from zero), but it carries the agreement's history and liabilities with it, which is exactly the successor-liability channel the overpayment section flagged. A buyer choosing between accepting the CHOW (continuity, inherited history) and rejecting it in favor of a fresh enrollment (clean slate, but a billing gap while the new enrollment processes) is making a diligence-informed decision, not a clerical one.

Medicaid and commercial re-enrollment. Medicaid enrollment runs state by state, each on its own timeline and its own forms, so a multi-state target multiplies the enrollment work. Commercial payers each run their own re-credentialing and re-contracting process, and a payer contract that is not assignable has to be renegotiated — sometimes at a lower rate. Payer-contract assignability is the quiet deal-shaper here: whether an agreement transfers or resets often influences the deal structure itself.

Credentialing is the gate inside the gate. Individual providers must be credentialed with each payer, and credentialing runs on its own cycle. CAQH requires providers to re-attest to their profile every 120 days (180 days in Illinois), or the profile status changes to Expired — the same canon our behavioral health data room guide details for credentialing continuity. A roster with lapsed attestations can stall network participation at precisely the moment the buyer needs uninterrupted billing, so the credentialing status of the provider roster is a diligence item, not an afterthought. Where a certificate of need (CON) or a state licensure transfer applies to the deal, add that regulatory approval to the critical path as well.

The timeline consequence. All of this is why regulated healthcare deals cluster at the longer end of the M&A duration curve. Across 334 M&A transactions on the Peony platform, blended time-to-close reached about 8.6 months in Q2 2026 (State of M&A Data Rooms, Q2 2026), and healthcare enrollment mechanics are part of why regulated deals sit toward the top of that range. The buyer's protection is to map the enrollment, re-credentialing, and licensure-transfer path during diligence and keep the evidence current in one place, so revenue continuity after close is something the buyer verified rather than assumed.

What do compliance, licensure, and regulatory workstreams cover?

The compliance and regulatory workstreams cover the fraud-and-abuse laws, the entity structure, and — where a device is involved — the FDA quality regime. This is the review that asks whether the way the target makes money is lawful, and in healthcare that question is separate from, and can override, whether the target is profitable.

Stark Law (Physician Self-Referral Law, 42 U.S.C. 1395nn). Stark prohibits a physician from referring designated health services payable by Medicare to an entity with which the physician (or an immediate family member) has a financial relationship, unless the arrangement fits a statutory or regulatory exception. The feature that makes Stark a diligence priority is that it is a strict-liability statute — intent is not required — so a technical defect in a physician compensation or lease arrangement can create real exposure even with no bad actor. Diligence therefore maps every physician financial arrangement to a specific exception and flags any that do not fit. A Stark problem also feeds the overpayment clock: claims tainted by a Stark violation can be overpayments that must be returned.

Anti-Kickback Statute (AKS, 42 U.S.C. 1320a-7b(b)). The AKS prohibits knowingly and willfully paying or receiving anything of value to induce or reward referrals of items or services payable by a federal healthcare program. Unlike Stark, the AKS is an intent-based criminal statute, and a violation can itself give rise to False Claims Act liability. Diligence reviews referral relationships, physician compensation tied to volume, and marketing and consulting arrangements against the AKS and its safe harbors.

Corporate practice of medicine (CPOM). CPOM is a matter of state law, and it is where many first-time healthcare buyers get surprised. A number of states restrict who may own a medical practice — often barring non-physician ownership of the professional entity — which is why the management-services-organization (MSO) structure exists: a non-physician-owned MSO provides administrative services to a physician-owned professional corporation under a management agreement. Diligence confirms that the target's structure actually satisfies the CPOM rules of every state it operates in, because a structure that violates CPOM can void contracts and create billing and licensure exposure.

The device overlay (QMSR), if the deal touches a product. If the target manufactures or markets a medical device — an imaging platform with proprietary hardware, a device-adjacent provider — the FDA quality regime enters the diligence set. As of February 2, 2026, FDA's Quality Management System Regulation (QMSR) is live: the final rule (Federal Register citation 89 FR 7496) rewrites 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, retires the old Design History File / Device Master Record / Device History Record vocabulary into the single ISO concept of the "Medical Device File," and — importantly for diligence — makes management-review and internal-audit records inspectable, which the old Quality System Regulation shielded. A buyer's regulatory counsel now wants to see those records because FDA can. This is the same QMSR canon our medical device M&A data room and imaging center M&A guides carry in full; if the deal is device-side, read those for the Medical Device File structure and the 510(k)/PMA layer. If it is a pure provider deal, the device overlay does not apply.

What does healthcare due diligence cost and how long does it take?

Healthcare due diligence cost scales with deal size and the number of workstreams engaged, and the healthcare-specific line items — the billing audit and the regulatory counsel — are the ones a generic diligence budget omits. The timeline runs longer than a comparable non-regulated deal because enrollment and credentialing sit on the critical path.

The cost stack. The financial workstream anchors on a quality-of-earnings engagement; a standard mid-market QoE runs several weeks and scales with deal size and data quality, and the cross-deal benchmarks live in our due diligence cost breakdown. The healthcare add-ons are what change the number:

• Billing and coding / revenue-cycle audit — usually a specialist firm, priced on the chart-review depth and the sample size. This is the line that produces the overpayment estimate, and it is where the specialist expertise is worth the fee.
• Regulatory counsel — for the Stark, AKS, CPOM, licensure, and enrollment review, and for structuring any self-disclosure.
• Payer-contract and enrollment analysis — assignability review and the change-of-ownership / re-credentialing mapping.

The exact figures vary too widely by deal size and complexity to publish a single reliable number, which is why I attribute the benchmark that I can stand behind rather than inventing a range: the deal-duration data.

The timeline. Regulated healthcare deals cluster at the longer end of the M&A duration curve. Across 334 M&A transactions on the Peony platform, blended time-to-close reached about 8.6 months in Q2 2026 (State of M&A Data Rooms, Q2 2026), and the enrollment, re-credentialing, and licensure-transfer mechanics push healthcare deals toward the top of that range. The single biggest lever on both cost and time is data quality: a complete, well-organized room on day one shortens every workstream, while a disorganized set adds weeks of pre-diligence cleanup before reviewers can start. That is a controllable variable, and it is the one this guide's data-room section is about.

For the index of first-party Peony datasets behind these numbers — deal duration, document volumes, feature adoption, and cost benchmarks — see Peony Research, where each dataset publishes with its methodology and update log.

How do you run the data room for healthcare due diligence?

You run a healthcare diligence room in five steps, all built around two facts that a generic deal room does not have to handle: the file is regulatory-heavy, and it is PHI-sensitive. The goal is a room where each workstream's reviewers work independently, the sensitive material stays gated, and PHI never becomes a liability.

1. Structure the folders on the provider-side eight-category tree. Lead with licensure and enrollment, then payer contracts, credentialing, quality, staffing, corporate, financials, and de-identified volume — the healthcare data room hub carries the full tree. Leading with the regulatory evidence makes gaps obvious: a missing DEA registration or a stale plan of correction shows up immediately rather than surfacing when a buyer's counsel asks.

2. Gate the room and stage the reveal. Nobody sees a file until they have signed an NDA, and the reveal is staged in tiers — a de-identified overview first, then financials and de-identified payer mix behind the gate, then the full payer contracts, detailed credentialing, and any billing detail held in a deeper post-LOI tier. Staging keeps the most sensitive material (payer rates, billing patterns) segregated from less-trusted parties, which matters when a plausible buyer might be a competitor.

3. Set permission groups per workstream. This is the healthcare-specific requirement. The billing reviewers, the regulatory counsel, the QoE team, and the payer-contract analysts each get their own granular permission group with its own view. The coding auditors see the billing sample; counsel sees the fraud-and-abuse and structure folders; the QoE team sees the financials. No reviewer sees a workstream they were not assigned, and when several bidders are in the process, one room per bidder means no bidder learns another is at the table.

4. Keep PHI out by default, and gate it with a BAA when it must enter. Share volume and quality data de-identified or in aggregate. Where a billing or chart audit genuinely needs PHI, have a signed BAA in place first, turn on dynamic watermarking so every page carries the viewer's identity, and enable screenshot protection. The cleaner discipline is still to de-identify before upload so there is nothing to redact; if you must redact identifiers in place, note that advanced redaction is a Deal Team-tier capability.

5. Track engagement. Watch the page-level analytics to see which reviewers are working which workstream and where they are stuck — useful for managing a multi-firm diligence team and for reading which bidders are serious.

The honest scope of the room. The data room is the exchange and evidence layer, not the audit tool. The chart-level coding audit is run by your specialist firm; the room gives that firm a walled, logged view of the sample and records who saw what. And for a mega-cap health-system process with millions of pages and a staffed, managed Q&A desk, an enterprise VDR (Datasite, Intralinks) is the right tool, and I would say so — that is a different job than the operator-run and mid-market provider deal this guide is about. Peony runs the mid-market healthcare diligence room on the Data Room plan at $52 per admin per month with unlimited rooms, dynamic watermarking, granular permissions, an exportable audit trail, and a BAA on request. Rooms set up in under 5 minutes because AI auto-indexing sorts a bulk upload into structure — so the slow part is gathering the regulatory documents, not building the room. This is the model behind Peony serving 6,800+ customers across M&A and healthcare.

What are the common mistakes in healthcare due diligence?

The common mistakes in healthcare due diligence cluster around treating it like a generic deal — underweighting the regulatory workstreams, mishandling PHI, and discovering the enrollment timeline after signing instead of during diligence. Each of these is avoidable, and each shows up repeatedly.

• Treating the financials as the whole review. The most common error is running a healthcare deal like any other and letting the QoE dominate while the regulatory streams get a light pass. In this vertical the regulatory review can override the financials — a clean-looking model on top of an unreturned overpayment or a Stark foot-fault is not a clean deal.
• Missing the 60-day overpayment exposure. Failing to run a billing and coding audit deep enough to surface a coding pattern leaves the buyer inheriting a multiplied FCA liability through successor liability. The audit is the step that sizes the risk so it can be structured.
• Putting PHI in the room without a BAA — or putting it in at all when it was not needed. Loading patient charts into a pre-close diligence room, without a signed BAA and without de-identifying first, turns the diligence file into a HIPAA liability. The default should be de-identified and aggregate; PHI enters only for a genuine chart audit, behind a BAA.
• Chasing a HIPAA "badge" instead of a BAA. Relying on a vendor's "HIPAA-certified" marketing rather than confirming a signed BAA and the Security Rule safeguards, because there is no government HIPAA certification to rely on.
• Discovering the enrollment timeline after signing. Not mapping the Medicare CHOW, Medicaid re-enrollment, commercial re-credentialing, and CAQH re-attestation status during diligence, then hitting a revenue gap after close when billing cannot continue uninterrupted.
• Ignoring payer-contract assignability. Assuming payer contracts transfer automatically, when many do not — an unassignable contract that has to be renegotiated at a lower rate can change the economics of the whole deal.
• Overlooking corporate practice of medicine. A non-physician buyer structuring an acquisition without confirming the CPOM rules of every state the target operates in, and building an MSO structure that does not actually satisfy them.

The unifying lesson is that healthcare diligence rewards leading with the regulatory and reimbursement questions and using the room to keep every workstream's evidence organized, gated, and auditable — so the review confirms a clean, transferable business rather than discovering, after close, that it bought someone else's liability.

---

Related Resources

• Healthcare Data Room Guide — the definitional hub: the provider-side eight-category document set and the deal-type router across the vertical
• Best HIPAA-Compliant Data Rooms — the matrix of which vendors actually sign a BAA, and on which tier
• Best Data Rooms for Healthcare and Life Sciences — the ranked provider comparison by clinical workflow
• Clinic Sale Data Room — the confidential quiet-sale playbook for physio, chiro, and rehab clinics
• Home Health Accreditation Data Room — where accreditation status and survey history drive the deal
• Behavioral Health Data Room — credentialing packs, payer audits, and the CAQH re-attestation cadence
• Imaging Center M&A Data Room — modality mix, equipment, and radiology-group contracts, with the QMSR overlay
• Medical Device M&A Data Room — 510(k)/PMA, the QMSR Medical Device File, and the regulatory-evidence layer
• Medical Equipment Sale Data Room — selling the equipment itself: service history, warranties, and title
• Pharma Partnering Data Room — the licensing and BD room for out-licensing a drug asset
• Biotech Data Room Guide — the nine-folder therapeutics document set for a life-science deal
• Clinical Trial Data Sharing — the de-identification and agreement mechanics for research data
• Best Healthcare M&A Advisors — the bankers and advisors who run these deals
• What Is Due Diligence? — the definitional root of the DD cluster
• M&A Due Diligence Process Guide — the full buy-side DD framework
• Due Diligence Cost Breakdown — comparative diligence costs across deal sizes
• Financial Due Diligence — add-backs, the working-capital peg, and normalization
• Quality of Earnings — the QoE that consumes the billing-audit error rate as an input
• HR Due Diligence — physician employment agreements, non-competes, and fair-market-value compensation
• Sell-Side Due Diligence — the seller-side version, for a provider preparing to go to market
• Legal Due Diligence — the general legal-workstream review and the change-of-control consent map behind payer-contract assignability
• Buy-Side Due Diligence — the general buy-side process this healthcare variant plugs into: 7 workstreams sequenced against the exclusivity clock

For healthcare due diligence specifically, Peony's data room — used by 6,800+ customers — gives each workstream its own permissioned folder so the billing reviewers, regulatory counsel, and QoE team work independently in one room; dynamic watermarking and screenshot protection for anything sensitive; a signed BAA on request when a billing or chart audit needs PHI; AI auto-indexing that sorts the regulatory file into structure in under 5 minutes; and an exportable audit trail that records who reviewed which evidence — the record a buyer wants if a dispute over what was disclosed ever arises. Try Peony free for 14 days — no credit card required.

About the author: Sean Yu is the co-founder of Peony, the data room platform used by 6,800+ customers across M&A, fundraising, and diligence workflows — including provider roll-ups and healthcare deal teams. Before Peony, Sean spent his career on the deal side — M&A at Nomura, early-stage VC at Backed VC, and growth-equity / secondaries at Target Global — running and supporting buy-side and sell-side processes across healthcare, software, and industrials in North America and Europe. He studied Biomedical Engineering at Imperial College London on a full scholarship before dropping out to build companies. Contact: sean@peony.ink • LinkedIn.

Sources

• eCFR — 42 CFR 401.305, Requirements for reporting and returning of overpayments — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-A/part-401/subpart-D/section-401.305
• Morgan Lewis — Tick-Tock: CMS Overpayment Refund Final Rule and Practical Implications (Dec 2024, effective Jan 1 2025; "knowingly" standard; 6-month suspension) — https://www.morganlewis.com/pubs/2024/12/tick-tock-cms-overpayment-refund-final-rule-and-practical-implications
• Foley & Lardner — Medicare Overpayments: CMS Final Regulations Implementing Changes to the 60-day Refund Rule — https://www.foley.com/insights/publications/2024/11/medicare-overpayments-cms-final-regulations-60-day-refund/
• Phillips & Cohen — False Claims Act civil penalty inflation adjustment ($14,308 minimum / $28,619 maximum per claim) — https://www.phillipsandcohen.com/fca-penalties-annual-increase-for-inflation/
• Federal Register — Civil Penalties Adjustment for 2026 (no 2026 inflation adjustment) — https://www.federalregister.gov/documents/2026/07/28/2026-15230/civil-penalties-adjustment-for-2026
• HHS-OIG — Self-Disclosure Protocol (minimum 1.5x damages multiplier) — https://oig.hhs.gov/compliance/self-disclosure-info/
• Kaufman Hall — M&A Quarterly Activity Report, Q1 2026 (22 announcements, $14.5B transacted revenue, $657M smaller-party avg, 6 of 22 for-profit) — https://www.kaufmanhall.com/insights/research-report/ma-quarterly-activity-report-q1-2026
• LevinPro HC — Healthcare M&A Deal Volume Drops in Q2:26 (459 announced transactions) — https://www.globenewswire.com/news-release/2026/07/30/3336197/0/en/Healthcare-M-A-Deal-Volume-Drops-in-Q2-26-According-to-Acquisition-Data-from-LevinPro-HC.html
• HHS — Guidance on De-identification of Protected Health Information (Safe Harbor, 45 CFR 164.514(b)(2)) — https://www.hhs.gov/hipaa/for-professionals/special-topics/de-identification/index.html
• HHS — HIPAA Security Rule (45 CFR Part 164, Subpart C) — https://www.hhs.gov/hipaa/for-professionals/security/index.html
• Cornell LII — Stark Law, 42 U.S.C. 1395nn — https://www.law.cornell.edu/uscode/text/42/1395nn
• Cornell LII — Anti-Kickback Statute, 42 U.S.C. 1320a-7b — https://www.law.cornell.edu/uscode/text/42/1320a-7b
• Peony — State of M&A Data Rooms, Q2 2026 (334 transactions; ~8.6 months blended time-to-close) — https://www.peony.ink/blog/state-of-ma-data-rooms
• Peony Research — first-party dataset index — https://www.peony.ink/research